Clinical and pharmacological factors related to the requirements of laser photocoagulation in patients with diabetic nephropathy due to type 2 diabetes mellitus

被引:1
|
作者
Auyanet, Ingrid [1 ]
Jose Rodriguez, Luis [2 ]
Yurena Sanchez, Ana [1 ]
Esparza, Noemi [1 ]
Cabrera, Francisco [2 ]
Bosch, Elvira [1 ]
Cardona, Pedro [2 ]
Dolores Checa, Maria [1 ]
机构
[1] Univ Gran Canaria, Hosp Insular, Serv Nefrol, Las Palmas Gran Canaria, Spain
[2] Univ Gran Canaria, Hosp Insular, Serv Oftalmol, Las Palmas Gran Canaria, Spain
来源
MEDICINA CLINICA | 2011年 / 137卷 / 04期
关键词
Light coagulation; Diabetic nephropathy; Diabetic retinopathy; ENDOTHELIAL GROWTH-FACTOR; MICROVASCULAR OUTCOMES; GLUCOSE CONTROL; BLOOD-PRESSURE; RETINOPATHY; COMPLICATIONS; PROGRESSION; PERINDOPRIL; BLOCKADE; TRIAL;
D O I
10.1016/j.medcli.2010.11.033
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and objetive: Diabetic retinopathy is a microvascular complication of diabetes mellitus whose prevalence is closely related to the presence of nephropathy and hypertension. The aim was to study clinical and pharmacological factors that are associated with an increased need for laser photocoagulation in patients with diabetic nephropathy and retinopathy. Patients and methods: Cross sectional study of 63 patients followed in the Diabetic Nephropathy consultation. Patients were divided into 2 groups according to whether or not previously have received photocoagulation. In each subgroup were studied demographic variables, anthropometric, laboratory, cardiovascular risk factors and treatment received by each patient for the control of hypertension, diabetes and others diseases. Results: We observed that the group had received photocoagulation had more years of diabetes evolution, more history of cardiovascular disease and a lower creatinine clearance. Similary, the percentage of patients treated with carvedilol was significantly higher in the subgroup who had not received photocoagulation while the percentage of patients treated with beta-blockers was significantly higher in the subgroup that received photocoagulation; no significant differences was observed in the degree of control blood pressure. Conclusions: Clinical and pharmacological factors related to the requirements of laser photocoagulation were years of diabetes evolution, history of cardiovascular disease, the stage of kidney disease and the treatment with beta-blokers. (C) 2010 Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:152 / 156
页数:5
相关论文
共 50 条
  • [21] Insomnia and Related Factors in Patients with Type 2 Diabetes Mellitus
    Yildiz, Busra
    Haliloglu, Ozlem
    Baran, Emre
    Afacan, Muhammed Yusuf
    Senel, Gulcin Benbir
    Siva, Zeynep Osar
    Karadeniz, Derya
    JOURNAL OF TURKISH SLEEP MEDICINE-TURK UYKU TIBBI DERGISI, 2020, 7 (03): : 106 - 111
  • [22] Clinical significance of serum homocysteine as a biomarker for early diagnosis of diabetic nephropathy in type 2 diabetes mellitus patients
    Ye, Bin
    Zhu, Xiangying
    Zeng, Zhifu
    Ji, Xiaozhen
    Ji, Meixia
    PTERIDINES, 2021, 32 (01) : 11 - 16
  • [23] Pre-clinical markers for diagnosis of diabetic nephropathy in patients with type 1 diabetes mellitus
    Lebedeva, N. O.
    Vikulova, O. K.
    DIABETES MELLITUS, 2012, 15 (02): : 38 - 45
  • [24] VALIDATION STUDY OF THE PATHOLOGIC CLASSIFICATION OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
    An Yu
    Xu Feng
    Le Weibo
    Ge Yongchun
    Zhou Minlin
    Zeng Caihong
    Liu Zhihong
    NEPHROLOGY, 2014, 19 : 47 - 47
  • [25] Treatment of diabetic nephropathy in patients with type 2 diabetes mellitus. Recent advances
    de Alvaro, F
    NEFROLOGIA, 2001, 21 : 76 - +
  • [26] Dyslipidaemia and cardiovascular risk in type 2 diabetes mellitus patients with associated diabetic nephropathy
    Martínez-Castelao, A
    Ramos, R
    González, MT
    Castiñeiras, MJ
    NEFROLOGIA, 2002, 22 : 51 - 58
  • [27] The prevalence of diabetic nephropathy in patients with type 2 diabetes mellitus in Slovakia: the NEFRITI Study
    Martinka, E.
    Pontuch, P.
    DIABETOLOGIA, 2015, 58 : S536 - S537
  • [28] The role of coagulation and inflammation in the development of diabetic nephropathy in patients with diabetes mellitus type 2
    Khasanova, Yu. V.
    Nelayeva, A. A.
    Galkina, A. B.
    Medvedeva, I. V.
    DIABETES MELLITUS, 2012, 15 (01): : 31 - 34
  • [29] The Search for Molecular Prognostic Markers of Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus
    Ibragimov, V. M.
    Sarvilina, I. V.
    Batiushin, M. M.
    INTERNATIONAL JOURNAL OF BIOMEDICINE, 2016, 6 (01) : 65 - 69
  • [30] ALCAM a novel biomarker in patients with type 2 diabetes mellitus complicated with diabetic nephropathy
    Sulaj, Alba
    Kopf, Stefan
    Grone, Elisabeth
    Grone, Hermann-Josef
    Hoffmann, Sigrid
    Schleicher, Erwin
    Haring, Hans-Ulrich
    Schwenger, Vedat
    Herzig, Stephan
    Fleming, Thomas
    Nawroth, Peter P.
    von Bauer, Rudiger
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2017, 31 (06) : 1058 - 1065